Collaboration between specialties for respiratory allergies in the International Classification of Diseases (ICD)-11 by Luciana Kase Tanno et al.
RESEARCH Open Access
Collaboration between specialties for
respiratory allergies in the International
Classification of Diseases (ICD)-11
Luciana Kase Tanno1,2,3*, Moises Calderon4, Jeffrey F. Linzer Sr5, Robert J.G. Chalmers6, Pascal Demoly2
and on behalf of the Joint Allergy Academies
Abstract
Background: The International Classification of Diseases (ICD) has been grouping the allergic and hypersensitivity
disorders involving the respiratory tract under topographic distribution, regardless of the underlying mechanisms,
triggers or concepts currently in use for allergic and hypersensitivity conditions. In order to strengthen awareness
and deliberate the creation of the new “Allergic or hypersensitivity disorders involving the respiratory tract” section
of the ICD-11, we here propose make the building process public.
Methods: The new frame has been constructed to cover the gaps previously identified and was based on consensus
academic reports and ICD-11 principles. Constant and bilateral discussion was kept with relevant groups representing
specialties and resulted in proposals submission into the ICD-11 online platform.
Results: The “Allergic or hypersensitivity disorders involving the respiratory tract” section covers 64 entities distributed
across five main categories. All the 79 proposals submitted resulted from an intensive collaboration of the Allergy
working group, relevant Expert working groups and the WHO ICD governance.
Conclusion: The establishment of the ICD-11 “Allergic or hypersensitivity disorders involving the respiratory tract”
section will allow the dissemination of the updated concepts to be used in clinical practice by many different
specialties and health professionals.
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World Health Organization (WHO)
Background
Allergic and hypersensitivity disorders involving the
respiratory tract
The World Health Organization (WHO) defines non-
communicable chronic respiratory diseases (CRDs) as
conditions of the airways and other structures of the
lung, such as asthma, chronic obstructive pulmonary
diseases (COPD), occupational lung diseases, cystic fibro-
sis and pulmonary hypertension. Changes in life-style and
in exposure to environmental pollutants and allergens
have increased both the prevalence and the severity of
CRDs in different age groups, with increased impact on
quality of life and healthcare costs, as has been shown
particularly for asthma.
Over the last few decades, the world has been facing
an asthma and allergy epidemic, becoming a serious
public health problem and a prominent cause of disabil-
ity and mortality worldwide. The WHO estimates that
about 235 million people currently suffer from asthma
[1]. Although most common in childhood, asthma can
persist into adulthood and the prevalence can vary
widely across the age groups [1].
Though asthma mortality rates are higher in lower and
lower-middle income countries, it has been accepted as
a major public health problem in all countries. Among
the European Union (EU) member states, asthma
accounted for an average of 53 hospital admissions per
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100,000 inhabitants in 2009 [2]. The annual direct and
indirect costs in European countries due to asthma are es-
timated at €22,2 billion and €16,4 billion respectively per
year. Data on the value of disability-adjusted life-years lost
due to asthma obtained from WHO Health Statistics 2011
and the Global Burden of Disease study indicate an esti-
mated monetized total cost of €43.2 billion [3, 4].
Allergic and hypersensitivity disorders involving the re-
spiratory tract comprise a range of different clinical pre-
sentations including asthma, rhinitis, and pneumonitis
among others. They can manifest at any age and in differ-
ing degrees of severity, frequently giving rise to a signifi-
cant impact on the quality of life of patients and their
families. They are likely to be encountered at some stage
by every health professional.
Many international initiatives have been launched to
prevent and decrease the negative outcome of these
conditions, which are considered a global health prob-
lem [5, 6]. However, international classification and
coding systems such as the International Classification
of Diseases (ICD) have grouped them under topographic
distribution, regardless of the underlying mechanisms and
triggers. This has led to the framework of both the 10th
and draft 11th revisions of ICD (ICD-10 2010 version and
ICD-11 beta draft as at May 2014 respectively) to be
deficient in capturing the concepts currently in use for
allergic and hypersensitivity conditions [7]. These findings
highlight the need for the major respiratory societies to be
involved in updating the representation of allergic and
hypersensitivity disorders involving the respiratory tract in
the ongoing ICD-11 revision.
Rationale for updating allergic and hypersensitivity
disorders involving the respiratory tract in the ICD-11
framework
The allergy specialty scope
Allergy and clinical immunology, while perceived as a
secondary discipline in some medical communities, has
been increasingly recognized around the world as a key
specialty in its own right [8, 9]. Unlike many other spe-
cialties, which focus mostly on specific organ systems,
the allergy discipline is a cross-cutting specialty, which
transcends such boundaries, in that allergists deal with
conditions involving multiple systems, often managing
them jointly with colleagues from “sister specialties” such
as respiratory medicine, pediatrics, dermatology, ophthal-
mology, otorhinolaryngology and gastroenterology. How-
ever, the terms currently used on a daily basis by allergists
are not all widely known by practitioners from the “sister
specialties” and their absence from health classification
and coding systems contributing to the misclassification
and/or under-representation of these entities in official
health statistics and, as a consequence, a tremendous
negative impact at many different levels on the manage-
ment of allergic disorders.
Understanding of the underlying mechanisms
Medical science’s understanding of the immune system
has advanced significantly over the last decade having
positive implications for both research and clinical prac-
tice. This development has led to an increasing number
of commercially available diagnostic tools as well as a
number of new products for the management of allergic
and hypersensitivity conditions. In general, there is now
an accepted understanding of the mechanisms underlying
the most important of them, enabling a comprehensive
range of “stem” concepts to be incorporated into ICD-11.
The “stem” concepts can then be further characterized
by appending further detail (e.g. triggers, chronology
and severity grading) to produce a sophisticated post-
coordinated expression (e.g. Drug-induced anaphylaxis:
grade III: due to benzylpenicillin).
From a public health perspective
Integration of a comprehensive allergic and hypersensitiv-
ity conditions classification into national and international
health information systems is crucial to the identification
of their health impact at both a national and a global level
and to help identify service deficiencies and provide the
motivation for change. Misconceptions about and under-
representation of common allergic disorders in healthcare
coding systems hinder clinical research and contribute to
a lack of ascertainment and poor recognition of their im-
portance for health care planning, resource allocation and
reimbursement.
For these reasons, we have considered it timely to up-
date the representation of allergic and hypersensitivity
conditions within ICD [10].
Methods
Allergy perspective of the ICD-11 revision
The ICD is a system of classifying medical diagnoses, de-
veloped and periodically revised by the WHO, providing
a common language both for health records and for epi-
demiological analyses of disease. The WHO started to
work on ICD-11 in 2007. A Revision Steering Group
(RSG) has overseen some 18 content-specific Topic Advis-
ory Groups (TAGs), each charged with updating sections
of the classification relevant to it, in collaboration where
necessary with other TAGs [10]. As new proposals come
forward they can be viewed and commented upon the on-
line ICD-11 beta draft [11].
The structure of ICD-11 is more complex than that of
its predecessors in that it is based on a ”Foundation”
from which a suite of different classifications or “views”
can be extracted, of which the principal is the core
ICD-11 for Mortality and Morbidity Statistics (ICD-11
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MMS), the direct replacement for ICD-10. The current
plans envisage that ICD-11 MMS will be finalized in
2018. In addition to the ICD-11 MMS this there is
scope for more detailed specialty classifications, which
could include one for Allergic disorders. The polyhier-
archical structure of the Foundation, in which an entity
may have more than one hierarchical parent, permits a
single condition to be represented in more than one lo-
cation, as explained in more detail below.
In contrast to previous revisions, the current ICD-11
draft is housed online and can receive external proposals
for consideration by the TAGs, RSG and WHO.
Realizing that the current ICD revision would offer a
unique opportunity to reach a better classification, defin-
ition and standardization of allergic and hypersensitivity
conditions, an international collaboration of Allergy
Academies has convened an Allergy Working Group
(AWG) which has worked tirelessly since 2013 on pro-
viding scientific evidence to support the need for
change and on developing an improved and up-to-date
classification of allergic disorders.
The actions so far have been supported and acknowl-
edged by the WHO ICD Revision Project staff, with whom
the AWG has been keeping bilateral continuous dialog,
and have been documented by a series of peer-reviewed
publications [7, 12–19]. The construction of the “Allergic
and hypersensitivity conditions” section of the new
ICD-11 chapter “Disorders of the immune system” has
involved numerous steps and would not have been pos-
sible if the AWG had not undertaken constant discussions
with the relevant TAGs [11].
Results
Classification of allergic or hypersensitivity disorders
involving the respiratory tract
The section of ICD-11 entitled “Allergic and hypersensi-
tivity disorders involving the respiratory tract” has been
constructed with full agreement of the involved TAGs and
Expert Working Groups (EWGs) (Fig. 1). The structure
was based on the overall design of the section “Allergic
and hypersensitivity diseases”, which was validated by
crowd-sourcing and simplified according to guidance
from members of the RSG. The discussion had the sci-
entific and technical basis to ensure comparability and
consistency. An intensive exchange of e-mails, tele- and
video-conferences started in February 2014 and was the
basis for what was submitted into the online ICD-11
beta draft proposal platform. All the actions of the
AWG have been undertaken with RSG guidance.
The ICD-11 beta draft supports a proposal system in
which four main types of proposal are possible: i) con-
tent enhancement proposal, ii) addition of new child en-
tity to an existing entity iii) deletion of an existing entity
and iv) complex hierarchical changes (Fig. 2). Each sub-
mitted proposal has to be supported by a rationale and
peer-reviewed references, and must follow an established
“content model”. The ICD-11 content model incorporates:
title, definition, synonyms, narrower terms, exclusions,
body system, body site, signs and symptoms, causal agents
and causal mechanisms [10]. The ICD-11 beta draft
Fig. 1 Collaboration between specialties for the construction of the
“Allergic or hypersensitivity disorders involving the respiratory tract”
(TAG = Topic Advisory Group)
Fig. 2 Purposes of the four main proposal type available in the ICD-11 beta draft platform
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platform [11] can be considered a WHO web-observatory
in which the members of the RSG and TAGs can monitor
proposal submissions and comments and can recommend
implementation or rejection of proposals.
The AWG carried out discussions with the relevant
TAGs and EWGs with whom it shared common inter-
ests; we started the submission process as soon as we
reached a consensus was reached. Most of the proposals
for the construction of this section were submitted be-
tween February and April 2014 but improvements have
continued to be made based on comments received.
During this process, the AWG submitted a total of 79
proposals, most of which (87.3%) have been implemented
(Fig. 3). We did not identify any entities which required to
be deleted.
Currently, the respiratory tract allergy and hypersensitivity
classification contains 64 entities distributed across 5 main
categories: i) Allergic and non-allergic rhinitis, ii) Hypersen-
sitivity pneumonitis, iii) Aspergillus-induced allergic or
hypersensitivity conditions, iv) Chronic rhinosinusitis and v)
Asthma. Two further entities have been added more re-
cently: “Drug-induced bronchospasm” and “Bronchospasm
provoked by allergy to food substance” (Fig. 4).
As explained above the ICD-11 Foundation is a poly-
hierarchical construct. Both entities Samter syndrome and
Allergic Aspergillus rhinosinusitis are represented in two
categories, meaning that Samter syndrome is displayed in
the ICD-11 Foundation as a child both of Chronic rhinosi-
nusitis and of Other specified asthma; and Allergic Asper-
gillus rhinosinusitis is displayed similarly as a child both of
Aspergillus-induced allergic or hypersensitivity conditions
and of Chronic rhinosinusitis. Although allergic ocular
conditions, such as allergic conjunctivitis usually coexist
with respiratory allergies, we did not include these dis-
orders under the “Allergic or hypersensitivity disorders
involving the respiratory tract” section since they are
classified under a specific section named “Allergic or
hypersensitivity disorders involving the eye”.
Fig. 3 Proposals submitted into the ICD-11 beta draft platform (November 2015 version) for the construction of the “Allergic and hypersensitivity
disorders involving the respiratory tract”
Fig. 4 The current “Allergic and hypersensitivity disorders involving the respiratory tract” section of the ICD-11 beta draft platform
(November 2015 version)
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The ICD-11 MMS permits only one hierarchical parent
for a given entity but does display entities that are located
primarily elsewhere to be shown as cross-references in
gray. As a consequence many of the entities to be found
in the “Allergic or hypersensitivity disorders involving the
respiratory tract “ section of the ICD-11 MMS are shown
as cross-references from the “Diseases of the respiratory
system” chapter.
Discussion
Lessons of the building process
The construction of a classification of respiratory allergies
was a labor-intensive and complicated process. The classi-
fication forms only a part of the new section on Allergic
and hypersensitivity conditions which WHO has accepted
for inclusion in the new Disorders of the immune system
chapter in ICD-11, thus for the first time enabling these
disorders to be properly represented in ICD.
In view of the fact that “Allergy” as a specialty crosses
boundaries between disciplines, many allergic and hyper-
sensitivity conditions are also relevant to other special-
ties. Intensive cooperation between the representatives
of different specialties enabled consensus to be reached
for the construction of the “Allergic or hypersensitivity
disorders involving the respiratory tract” section. As an
example the proposal that “Bronchospasm provoked by al-
lergy to food substances” should be placed within “Allergic
or hypersensitivity disorders involving the respiratory
tract” was put forward by the Dermatology TAG and then
agreed by the Respiratory EWG of the Internal Medicine
TAG, the AWG and the Pediatric TAG.
More than a mere discussion of classification, these inter-
actions helped us to develop a common vision for handling
concepts, terminology and ontology. Throughout this sys-
tematic process and after a fruitful discussion we were able
to capture the “external” real understanding of how allergy
and hypersensitivity conditions are perceived by others.
This provided us with a global view of the key issues to be
managed in order to strengthen the allergy specialty.
Conclusion
The establishment of the ICD-11 “Allergic or hypersensi-
tivity disorders involving the respiratory tract” section, as
well as the other sessions of the “Allergic and hypersensi-
tivity conditions” chapter will allow the dissemination of
the updated concepts to be used in clinical practice by
many different specialties and health professionals.
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